Johnson Fistel is investigating Fulcrum Therapeutics for potential federal securities law violations following the company's June 1, 2026 announcement to discontinue its lead sickle cell drug pociredir due to FDA concerns about PRC2 complex targeting therapies carrying malignancy risks. The disclosure caused a sharp stock price decline, prompting the law firm to investigate potential investor losses and recovery options.

Fulcrum Therapeutics (NASDAQ: FULC) shares plunged 49.69% in after-hours trading after announcing the discontinuation of pociredir, its lead experimental drug for sickle cell disease, due to FDA concerns about cancer-related risks associated with PRC2 pathway targeting drugs. The company launched a strategic review process to explore merger, acquisition, or other alternatives to maximize shareholder value while preserving its $333.3 million in cash reserves.

Fulcrum Therapeutics reported positive clinical data for pociredir showing robust fetal hemoglobin induction and improvements in hemolysis markers in sickle cell disease patients. The company plans to initiate a registration-enabling trial in H2 2026 and ended Q1 with $333.3 million in cash, providing runway into 2029. CFO Alan Musso will retire later this year, and Dr. Josh Lehrer joined the board.

MedicAlert Foundation, the Sickle Cell Disease Association of America (SCDAA), and Fulcrum Therapeutics announced a three-year partnership to improve emergency department care for sickle cell disease patients. The collaboration provides participants with MedicAlert Smart Medical ID Cards linked to secure digital health profiles containing physician-approved pain plans and vital medical information accessible via QR code scanning, aiming to expedite care during acute pain crises.

Fulcrum Therapeutics reported positive 12-week data from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. The drug demonstrated robust fetal hemoglobin (HbF) induction with mean absolute HbF increasing by 12.2% (from 7.1% to 19.3%), 58% of patients achieving HbF levels ≥20%, and 58% reporting zero vaso-occlusive crises during treatment. The drug was generally well-tolerated with no treatment-related serious adverse events. Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 pending FDA feedback.

The U.S. firmware signing platform market is projected to grow from $0.40B in 2025 to $1.39B by 2033, driven by increasing demand for secure device updates across IoT, automotive, medical, and industrial systems, with a 16.78% CAGR.

Fulcrum Therapeutics has priced a public offering of 11,851,853 common stock shares and pre-funded warrants, expecting to raise $175.0 million to fund research, development, and potential acquisitions.

Fulcrum Therapeutics reported positive Phase 1b trial results for pociredir, an oral medication for sickle cell disease, showing significant increases in fetal hemoglobin and promising safety profile at the 20 mg dose level.

Datanomix and Fulcrum announced a strategic partnership to integrate ERP and production monitoring technologies, enabling manufacturers to unify job planning, scheduling, and live production tracking with real-time insights.

Fulcrum Therapeutics granted 47,450 non-statutory stock options to new employees at $9.50 per share, with a ten-year term and four-year vesting schedule.

Fulcrum Therapeutics granted 35,000 non-statutory stock options to a new employee at $7.27 per share, with a ten-year term and four-year vesting schedule.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted stock options to a new employee as an inducement to join the company.